Testosterone Drug Liability Lawsuits

Dozens of testosterone drug liability lawsuits have been filed claiming the drugs have caused heart attacks, strokes, pulmonary embolisms, deep vein thrombosis, blood clots, and even death, among men taking testosterone or "Low T" drugs.

The prescriptions for testosterone supplements have doubled within the past five years, which many believe is due to an aggressive marketing campaign led by the drug companies. These advertising campaigns have urged men to seek treatment for Low T, which includes symptoms of fatigue, loss of energy, low libido, and sagging muscle tone. Testosterone drugs are among the fastest growing prescriptions among younger men.

These testosterone drugs are often marketed under the following brand names:

AndroGel

Androderm

Bio-T Gel

Delatestryl

Depo Testosterone

Fortesta

Striant

Testim

Testioderm

Testopel

The Food and Drug Administration ("FDA") is currently investigating whether men taking these drugs are at an increased risk for heart attack and stroke. While the FDA is still evaluating these claims and has yet to make any conclusions on the safety of the drugs, a study by the Journal of the American Medical Association was released in November 2013 which suggested that there was a 30 percent increased risk of heart attack, stroke, and death in those men in the study that were prescribed testosterone therapy. Another study released in January 2014 reported that men age 65 and older were two times more likely to suffer a heart attack within the first 90 days of testosterone therapy and men under the age of 65 who had pre-existing histories of heart disease were two to three times more likely to suffer a heart attack after they began testosterone therapy.

Currently, there are dozens of testosterone drug liability lawsuits against the various manufacturers pending in federal courts across the nation. In April 2014, an application was made to consolidate all of the cases in a Multidistrict Litigation ("MDL") lawsuit, thereby allowing all the individual cases to be heard in front of one judge. It is anticipated that a decision determining whether the Low T lawsuits will be granted MDL status will made after May 29, 2014.

Categories:

Put the dedicated team at Dreyer Boyajian LLP in your corner.

    • Please enter your name.
    • This isn't a valid phone number.
      Please enter your phone number.
    • This isn't a valid email address.
      Please enter your email address.
    • Please make a selection.
    • Please enter a message.
Put Us On Your Side